Survival of HER2-Positive Breast Cancer Cells: Receptor Signaling to Apoptotic Control Centers

Genes and Cancer

Volumn 4, Issue 5-6, 2013, Pages 187-195

  Fink, Marc Y ^a   Chipuk, Jerry E ^b  

^a LONG ISLAND UNIVERSITY   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

AKT; BAD; BCL 2; lapatinib; mTOR; trastuzumab

Indexed keywords

A RAF KINASE; ANGIOPOIETIN RECEPTOR; B RAF KINASE; BH3 PROTEIN; BIM PROTEIN; CD135 ANTIGEN; EPHRIN RECEPTOR A1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 2; LAPATINIB; OBATOCLAX; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN MCL 1; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE A; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR FOXO; TRASTUZUMAB; UNINDEXED DRUG;

ANGIOGENESIS; APOPTOSIS; ARTICLE; BINDING SITE; BREAST CANCER; CANCER CELL; CARCINOGENESIS; CELL SURVIVAL; DOWN REGULATION; DRUG PROTEIN BINDING; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REGULATION; GENE OVEREXPRESSION; GENE REPRESSION; HUMAN; IMMUNOPRECIPITATION; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; UBIQUITINATION; UPREGULATION;

EID: 84887465848     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601913488598     Document Type: Article

References (108)

1. Slamon DJ,Clark GM,Wong SG, et al.Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.Science. 1987;235:177-82.
2. Ross JS,Fletcher JA.The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.Stem Cells. 1998;16:413-28.
3. Carter P,Presta L,Gorman CM, et al.Humanization of an anti-p185HER2 antibody for human cancer therapy.Proc Natl Acad Sci U S A. 1992;89:4285-9.
4. Valabrega G,Montemurro F,Aglietta M.Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.Ann Oncol. 2007;18:977-84.
5. Hudis CA.Trastuzumab: mechanism of action and use in clinical practice.N Engl J Med. 2007;357:39-51.
6. Albanell J,Codony J,Rovira A,Mellado B,Gascon P.Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4.Adv Exp Med Biol. 2003;532:253-68.
7. Spector NL,Blackwell KL.Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.J Clin Oncol. 2009;27:5838-47.
8. Cobleigh MA,Vogel CL,Tripathy D, et al.Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.J Clin Oncol. 1999;17:2639-48.
9. Baselga J,Tripathy D,Mendelsohn J, et al.Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.J Clin Oncol. 1996;14:737-44.
10. Slamon DJ,Leyland-Jones B,Shak S, et al.Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.N Engl J Med. 2001;344:783-92.
11. Esteva FJ,Valero V,Booser D, et al.Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.J Clin Oncol. 2002;20:1800-8.
12. Vogel CL,Cobleigh MA,Tripathy D, et al.Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.J Clin Oncol. 2002;20:719-26.
13. Seidman AD,Fornier MN,Esteva FJ, et al.Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.J Clin Oncol. 2001;19:2587-95.
14. Mukohara T.Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer.Cancer Sci. 2011;102:1-8.
15. Hubalek M,Brunner C,Mattha K,Marth C.Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment.Wien Med Wochenschr. 2010;160:506-12.
16. Kruser TJ,Wheeler DL.Mechanisms of resistance to HER family targeting antibodies.Exp Cell Res. 2010;316:1083-100.
17. Campone M,Juin P,Andre F,Bachelot T.Resistance to HER2 inhibitors: is addition better than substitution? Rationale for the hypothetical concept of drug sedimentation.Crit Rev Oncol Hematol. 2011;78:195-205.
18. Gajria D,Chandarlapaty S.HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.Expert Rev Anticancer Ther. 2011;11:263-75.
19. Depowski PL,Rosenthal SI,Ross JS.Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer.Mod Pathol. 2001;14:672-6.
20. Nagata Y,Lan KH,Zhou X, et al.PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.Cancer Cell. 2004;6:117-27.
21. Scaltriti M,Rojo F,Ocana A, et al.Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.J Natl Cancer Inst. 2007;99:628-38.
22. Shattuck DL,Miller JK,Carraway KL,Sweeney C.Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells.Cancer Res. 2008;68:1471-7.
23. Lu Y,Zi X,Zhao Y,Mascarenhas D,Pollak M.Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).J Natl Cancer Inst. 2001;93:1852-7.
24. Nahta R,Yuan LX,Zhang B,Kobayashi R,Esteva FJ.Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells.Cancer Res. 2005;65:11118-28.
25. Browne BC,Crown J,Venkatesan N, et al.Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells.Ann Oncol. 2011;22:68-73.
26. Esparis-Ogando A,Ocana A,Rodriguez-Barrueco R, et al.Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells.Ann Oncol. 2008;19:1860-9.
27. Huang X,Gao L,Wang S, et al.Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to Herceptin.Cancer Res. 2010;70:1204-14.
28. Nagy P,Friedlander E,Tanner M, et al.Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a Herceptin-resistant, MUC4-expressing breast cancer cell line.Cancer Res. 2005;65:473-82.
29. Geyer CE,Forster J,Lindquist D, et al.Lapatinib plus capecitabine for HER2-positive advanced breast cancer.N Engl J Med. 2006;355:2733-43.
30. Rusnak DW,Lackey K,Affleck K, et al.The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.Mol Cancer Ther. 2001;1:85-94.
31. Rusnak DW,Affleck K,Cockerill SG, et al.The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.Cancer Res. 2001;61:7196-203.
32. Xia W,Mullin RJ,Keith BR, et al.Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.Oncogene. 2002;21:6255-63.
33. Xia W,Bacus S,Hegde P, et al.A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer.Proc Natl Acad Sci U S A. 2006;103:7795-800.
34. Liu L,Greger J,Shi H, et al.Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.Cancer Res. 2009;69:6871-8.
35. Wilson TR,Fridlyand J,Yan Y, et al.Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.Nature. 2012;487:505-9.
36. Huang C,Park CC,Hilsenbeck SG, et al.beta1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib.Breast Cancer Res. 2011;13:R84.
37. Jegg AM,Ward TM,Iorns E, et al.PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells.Breast Cancer Res Treat. 2012;136:683-92.
38. Chakrabarty A,Sanchez V,Kuba MG,Rinehart C,Arteaga CL.Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors.Proc Natl Acad Sci U S A. 2012;109:2718-23.
39. Chandarlapaty S,Sawai A,Scaltriti M, et al.AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity.Cancer Cell. 2011;19:58-71.
40. Garrett JT,Olivares MG,Rinehart C, et al.Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase.Proc Natl Acad Sci U S A. 2011;108:5021-6.
41. Hegde PS,Rusnak D,Bertiaux M, et al.Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles.Mol Cancer Ther. 2007;6:1629-40.
42. Sangodkar J,Dhawan NS,Melville H, et al.Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response.J Clin Invest. 2012;122:2637-51.
43. Yarden Y.The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities.Eur J Cancer. 2001;37:S3-8.
44. Yarden Y,Sliwkowski MX.Untangling the ErbB signalling network.Nat Rev Mol Cell Biol. 2001;2:127-37.
45. Holbro T,Beerli RR,Maurer F, et al.The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation.Proc Natl Acad Sci U S A. 2003;100:8933-8.
46. Callans LS,Naama H,Khandelwal M,Plotkin R,Jardines L.Raf-1 protein expression in human breast cancer cells.Ann Surg Oncol. 1995;2:38-42.
47. Yoon S,Seger R.The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions.Growth Factors. 2006;24:21-44.
48. Shaul YD,Seger R.The MEK/ERK cascade: from signaling specificity to diverse functions.Biochim Biophys Acta. 2007;1773:1213-26.
49. Romeo Y,Zhang X,Roux PP.Regulation and function of the RSK family of protein kinases.Biochem J. 2012;441:553-69.
50. Anjum R,Blenis J.The RSK family of kinases: emerging roles in cellular signalling.Nat Rev Mol Cell Biol. 2008;9:747-58.
51. Stratford AL,Reipas K,Hu K, et al.Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers.Stem Cells. 2012;30:1338-48.
52. Smith JA,Poteet-Smith CE,Xu Y, et al.Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation.Cancer Res. 2005;65:1027-34.
53. Dhillon J,Astanehe A,Lee C, et al.The expression of activated Y-box binding protein-1 serine 102 mediates trastuzumab resistance in breast cancer cells by increasing CD44+ cells.Oncogene. 2010;29:6294-300.
54. Sweeney C,Fambrough D,Huard C, et al.Growth factor-specific signaling pathway stimulation and gene expression mediated by ErbB receptors.J Biol Chem. 2001;276:22685-98.
55. Nguyen TL.Targeting RSK: an overview of small molecule inhibitors.Anticancer Agents Med Chem. 2008;8:710-6.
56. Franke TF.PI3K/Akt: getting it right matters.Oncogene. 2008;27:6473-88.
57. Wu Y,Shang X,Sarkissyan M,Slamon D,Vadgama JV.FOXO1A is a target for HER2-overexpressing breast tumors.Cancer Res. 2010;70:5475-85.
58. Chou MM,Blenis J.The 70 kDa S6 kinase: regulation of a kinase with multiple roles in mitogenic signalling.Curr Opin Cell Biol. 1995;7:806-14.
59. Fenton TR,Gout IT.Functions and regulation of the 70kDa ribosomal S6 kinases.Int J Biochem Cell Biol. 2011;43:47-59.
60. Inoki K,Li Y,Zhu T,Wu J,Guan KL.TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling.Nat Cell Biol. 2002;4:648-57.
61. Potter CJ,Pedraza LG,Xu T.Akt regulates growth by directly phosphorylating Tsc2.Nat Cell Biol. 2002;4:658-65.
62. Garami A,Zwartkruis FJ,Nobukuni T, et al.Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2.Mol Cell. 2003;11:1457-66.
63. Danial NN,Korsmeyer SJ.Cell death: critical control points.Cell. 2004;116:205-19.
64. Chipuk JE,Moldoveanu T,Llambi F,Parsons MJ,Green DR.The BCL-2 family reunion.Mol Cell. 2010;37:299-310.
65. Li P,Nijhawan D,Budihardjo I, et al.Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade.Cell. 1997;91:479-89.
66. Srinivasula SM,Ahmad M,Fernandes-Alnemri T,Alnemri ES.Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization.Mol Cell. 1998;1:949-57.
67. Altieri DC.Survivin and IAP proteins in cell-death mechanisms.Biochem J. 2010;430:199-205.
68. Campone M,Noel B,Couriaud C, et al.c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1.Mol Cancer. 2011;10:110.
69. Perciavalle RM,Stewart DP,Koss B, et al.Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration.Nat Cell Biol. 2012;14:575-83.
70. Cruickshanks N,Tang Y,Booth L, et al.Lapatinib and obatoclax kill breast cancer cells through reactive oxygen species-dependent endoplasmic reticulum stress.Mol Pharmacol. 2012;82:1217-29.
71. Crawford A,Nahta R.Targeting Bcl-2 in Herceptin-resistant breast cancer cell lines.Curr Pharmacogenomics Person Med. 2011;9:184-90.
72. Tanizaki J,Okamoto I,Fumita S, et al.Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.Oncogene. 2011;30:4097-106.
73. Mitchell C,Yacoub A,Hossein H, et al.Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo.Cancer Biol Ther. 2010;10:903-17.
74. Ding Q,Huo L,Yang JY, et al.Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer.Cancer Res. 2008;68:6109-17.
75. Faber AC,Li D,Song Y, et al.Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition.Proc Natl Acad Sci U S A. 2009;106:19503-8.
76. Milella M,Trisciuoglio D,Bruno T, et al.Trastuzumab down- regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene-amplified breast cancer cells.Clin Cancer Res. 2004;10:7747-56.
77. Yang E,Zha J,Jockel J, et al.Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death.Cell. 1995;80:285-91.
78. Datta SR,Dudek H,Tao X, et al.Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery.Cell. 1997;91:231-41.
79. Fang X,Yu S,Eder A, et al.Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway.Oncogene. 1999;18:6635-40.
80. Scheid MP,Duronio V.Dissociation of cytokine-induced phosphorylation of Bad and activation of PKB/akt: involvement of MEK upstream of Bad phosphorylation.Proc Natl Acad Sci U S A. 1998;95:7439-44.
81. Shimamura A,Ballif BA,Richards SA,Blenis J.Rsk1 mediates a MEK-MAP kinase cell survival signal.Curr Biol. 2000;10:127-35.
82. Eisenmann KM,VanBrocklin MW,Staffend NA,Kitchen SM,Koo HM.Mitogen-activated protein kinase pathway-dependent tumor-specific survival signaling in melanoma cells through inactivation of the proapoptotic protein bad.Cancer Res. 2003;63:8330-7.
83. Zhou XM,Liu Y,Payne G,Lutz RJ,Chittenden T.Growth factors inactivate the cell death promoter BAD by phosphorylation of its BH3 domain on Ser155.J Biol Chem. 2000;275:25046-51.
84. Lizcano JM,Morrice N,Cohen P.Regulation of BAD by cAMP-dependent protein kinase is mediated via phosphorylation of a novel site, Ser155.Biochem J. 2000;349:547-57.
85. She QB,Solit DB,Ye Q, et al.The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells.Cancer Cell. 2005;8:287-97.
86. Vannini I,Zoli W,Fabbri F, et al.Role of efflux pump activity in lapatinib/caelyx combination in breast cancer cell lines.Anticancer Drugs. 2009;20:918-25.
87. Elkholi R,Floros KV,Chipuk JE.The role of BH3-only proteins in tumor cell development, signaling, and treatment.Genes Cancer. 2011;2:523-37.
88. Dijkers PF,Medema RH,Lammers JW,Koenderman L,Coffer PJ.Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1.Curr Biol. 2000;10:1201-4.
89. Harada H,Quearry B,Ruiz-Vela A,Korsmeyer SJ.Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity.Proc Natl Acad Sci U S A. 2004;101:15313-7.
90. Hubner A,Barrett T,Flavell RA,Davis RJ.Multisite phosphorylation regulates Bim stability and apoptotic activity.Mol Cell. 2008;30:415-25.
91. Dehan E,Bassermann F,Guardavaccaro D, et al.betaTrCP- and Rsk1/2-mediated degradation of BimEL inhibits apoptosis.Mol Cell. 2009;33:109-16.
92. Czernick M,Rieger A,Goping IS.Bim is reversibly phosphorylated but plays a limited role in paclitaxel cytotoxicity of breast cancer cell lines.Biochem Biophys Res Commun. 2009;379:145-50.
93. Haenssen KK,Caldwell SA,Shahriari KS, et al.ErbB2 requires integrin alpha5 for anoikis resistance via Src regulation of receptor activity in human mammary epithelial cells.J Cell Sci. 2010;123:1373-82.
94. Hubner A,Cavanagh-Kyros J,Rincon M,Flavell RA,Davis RJ.Functional cooperation of the proapoptotic Bcl2 family proteins Bmf and Bim in vivo.Mol Cell Biol. 2010;30:98-105.
95. Schmelzle T,Mailleux AA,Overholtzer M, et al.Functional role and oncogene-regulated expression of the BH3-only factor Bmf in mammary epithelial anoikis and morphogenesis.Proc Natl Acad Sci U S A. 2007;104:3787-92.
96. Kutuk O,Letai A.Displacement of Bim by Bmf and Puma rather than increase in Bim level mediates paclitaxel-induced apoptosis in breast cancer cells.Cell Death Differ. 2010;17:1624-35.
97. Lei K,Davis RJ.JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis.Proc Natl Acad Sci U S A. 2003;100:2432-7.
98. Whelan KA,Caldwell SA,Shahriari KS, et al.Hypoxia suppression of Bim and Bmf blocks anoikis and luminal clearing during mammary morphogenesis.Mol Biol Cell. 2010;21:3829-37.
99. Petry IB,Fieber E,Schmidt M, et al.ERBB2 induces an antiapoptotic expression pattern of Bcl-2 family members in node-negative breast cancer.Clin Cancer Res. 2010;16:451-60.
100. Wolf-Yadlin A,Kumar N,Zhang Y, et al.Effects of HER2 overexpression on cell signaling networks governing proliferation and migration.Mol Syst Biol. 2006;2:54.
101. Kumar N,Wolf-Yadlin A,White FM,Lauffenburger DA.Modeling HER2 effects on cell behavior from mass spectrometry phosphotyrosine data.PLoS Comput Biol. 2007;3:e4.
102. Imami K,Sugiyama N,Imamura H, et al.Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways.Mol Cell Proteomics. 2012;11:1741-57.
103. Birtwistle MR,Hatakeyama M,Yumoto N, et al.Ligand-dependent responses of the ErbB signaling network: experimental and modeling analyses.Mol Syst Biol. 2007;3:144.
104. Nelander S,Wang W,Nilsson B, et al.Models from experiments: combinatorial drug perturbations of cancer cells.Mol Syst Biol. 2008;4:216.
105. Iadevaia S,Lu Y,Morales FC,Mills GB,Ram PT.Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis.Cancer Res. 2010;70:6704-14.
106. Lu Y,Muller M,Smith D, et al.Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling.Oncogene. 2011;30:4567-77.
107. Marcotte R,Brown KR,Suarez F, et al.Essential gene profiles in breast, pancreatic, and ovarian cancer cells.Cancer Discov. 2012;2:172-89.
108. Koh JL,Brown KR,Sayad A, et al.COLT-Cancer: functional genetic screening resource for essential genes in human cancer cell lines.Nucleic Acids Res. 2012;40:D957-63.